|
Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Clinical research trials and Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma. Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma  Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma
Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma
For Condition: recurrent grade 3 follicular lymphoma,recurrent adult diffuse large cell lymphoma
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining bortezomib with combination chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effect of bortezomib with or without combination chemotherapy on the body and its effectiveness in treating patients who have relapsed or refractorylargeB-cell lymphoma.
Details: OBJECTIVES: - Determine the response rate of patients with relapsed or refractory diffuse large B-cell lymphoma within the activated and germinal center B cell-like molecular subtypes treated with bortezomib alone or with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH). - Determine the maximum tolerated dose of bortezomib administered in combination with EPOCH in patients who do not achieve a complete remission or progress with bortezomib alone. - Determine the toxicity of this combination regimen in these patients. - Determine the biological effect of bortezomib on tumor biopsies, including bcl-2 and NF-kappa B, using DNA microarray profiling and immunohistochemistry in these patients. - Correlate markers of drug resistance (bcl-2, MIB-1, and p53) with response in patients treated with this combination regimen. OUTLINE: This is a 2-part study. Part II is a dose-escalation study of bortezomib. Patients who require an immediate treatment response for medical reasons only receive therapy in part II. - Part I (Bortezomib alone): Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks. Patients who are candidates for autologous or allogeneic stem cell transplantation may receive up to 6 courses. Patients with progressive or stable disease after 2 courses may proceed to therapy in part II. Patients in complete remission may be referred for transplantation. Patients who are not candidates for transplantation but who have stable or responding disease may receive bortezomib for up to 1 year. Patients with disease progression after any course may proceed to therapy in part II. - Patients receive EPOCH comprising etoposide IV, doxorubicin IV, and vincristine IV continuously on days 1-4; cyclophosphamide IV over 15 minutes on day 5; and oral prednisone twice daily on days 1-5. Patients also receive bortezomib IV over 3-5 seconds on days 1 and 4 and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts recover. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceeding that at which no more than 1 of 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed relapsed or refractory large B-cell lymphoma of 1 of the following subtypes: - Diffuse - Mediastinal (thymic) - Transformed - Follicular grade IIIB - Intravascular - Tumor tissue available for biopsy - Prior anthracycline-based treatment required - No active CNS lymphoma PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,000/mm^3* - Platelet count at least 50,000/mm^3* NOTE: *Unless impairment due to organ involvement by lymphoma Hepatic - Bilirubin less than 2 mg/dL (5 mg/dL in patients with Gilbert's syndrome [defined by greater than 80% unconjugated])* - AST less than 5 times upper limit of normal* - Hepatitis B surface antigen negative NOTE: *Unless impairment due to organ involvement by lymphoma Renal - Creatinine no greater than 1.5 mg/dL* OR - Creatinine clearance greater than 60 mL/min* NOTE: *Unless impairment due to organ involvement by lymphoma Cardiovascular - Cardiac ejection fraction at least 40%* - No symptomatic cardiac disease* NOTE: *For patients receiving EPOCH chemotherapy Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - More than 4 weeks since prior systemic cytotoxic therapy - More than 4 weeks since prior experimental therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LouisStaudt, Study Chair, Metabolism Branch
Ireland Cancer Center *Recruiting*
Cleveland, Ohio, 44106
United States
Recruiting Omer Koc 216-244-1274
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support *Recruiting*
Bethesda, Maryland, 20892-1182
United States
Recruiting Patient Recruitment 888-NCI-1937
Additional Information:
Study ID Numbers: CDR0000285625; NCI-5748,NCI-03-C-0096
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057902
Other Recurrent Adult Diffuse Large Cell Lymphoma Studies:
1. Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
2. Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma
3. Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
4. MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
5. FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
Related Studies:
Other recurrent adult diffuse large cell lymphoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma
|
|
|
|
|
|
|
|
